AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside

• The company has already started the required safety studies and aims to begin its first human trial of AKTX-101 by mid-2027.
• Separately, Akari raised about $5.5 million by selling shares and warrants in a private placement. 
• The money will help move the drug toward human testing and cover general corporate needs.

Shares of Akari Therapeutics (AKTX) skyrocketed more than 133% in after-hours trading on Thursday after the clinical-stage biotech company reported breakthrough preclinical data on its lead cancer therapy and announced a $5.5 million private placement to fund further development.

Akari said its experimental therapy AKTX-101 showed strong results when paired with an already-approved cancer drug in lab tests on pancreatic cancer cells that carry a common KRAS mutation—one of the toughest cancers to treat. AKTX-101 is an antibody-drug conjugate, a type of targeted therapy that destroys cancer cells while sparing healthy tissue. The new data suggested the combination killed cancer cells far more effectively than either drug alone.

The company has already started the required safety studies and aims to begin its first human trial of AKTX-101 by mid-2027.

Separately, Akari raised about $5.5 million by selling shares and warrants in a private placement. The money will help move the drug toward human testing and cover general corporate needs.

“This financing reflects deep conviction from our long-term strategic investors and positions Akari to build on our strong momentum,” said CEO Abizer Gaslightwala. He also added that the preclinical data for AKTX-101 highlight the potential to enhance the activity of approved therapies.

How Did AKTX Retail Traders React?

On Stocktwits, retail sentiment around AKTX stock improved from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.

A Stocktwits user expressed optimism for a major rally on Thursday.

Another user warned that the experimental drug has yet to enter clinical studies.

According to data from Koyfin, one of the two analysts covering AKTX rates it a ‘Buy’ while the other rates it ‘Hold.’ The 12-month average price target on the stock is $26.78, representing a potential upside of over 420% from the last close.

AKTX stock has fallen 90% over the past 12 months. 

Read More: BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial

For updates and corrections, email newsroom[at]stocktwits[dot]com.